Welcome to Flow Pharma Inc.

Page Loading...


Powerful Immunotherapy

in a Stable Dry Powder

Delivery Methods

  • Anti-Virus – inhalation & intramuscular

  • Anti-Cancer – intranodal & intramuscular

No animal-sourced material. No live or dead virus. Does not rely on DNA or RNA transcription.

Rapidly Scalable

Biological Weapon Defense

Ebola/Marburg has reportedly been weaponized in Eastern Europe.


Protective vaccination against this threat may be possible with the FlowVax Platform.


Department of Defense funded vaccine development is happening now at Flow Pharma.

Under Development, FDA approval required.



A New Vaccine for COVID-19. Administered by inhaler. FLOVID-20 is designed to treat and prevent all known variants by inhaler or by injection.


X-rays of COVID-19 exposed monkeys.


The left monkey was treated with inhaled FLOVID-20.

Under Development, FDA approval required.

New Hope for Treatment-Resistant Breast Cancer

FlowVax BreastCA is an immunotherapy solution for breast cancer.


Flow Pharma’s targeted medicine may slow tumor growth.

Under Development, FDA approval required.

Our Mission

Flow Pharma is dedicated to immunotherapy innovation.

Our exclusive technology and manufacturing expertise are poised to transform the treatment and prevention of cancer and viral disease.

Product Portfolio



An inhaled treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations.

FlowVax Ebola/Marburg

Ebola, Marburg

Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target these viruses, long-lasting infection prevention is attainable.

FlowVax BreastCA


A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.

FlowVax HPV

Cancer, HPV

A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.

Subscribe to Flow Pharma Updates